Novartis on course to set new highs
20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."
Pages
71
Language
English
Published on
20/02/24
You may also be interested by these reports :
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...
28/10/26
The Q3 profitability exceeded expectations, though sales came in line with consensus. The strong showing in ‘Specialty medicines’ made up for the ...
28/10/26
The Q3 sales missed consensus because of near-term biosimilar supply constraints, pricing pressure in Germany and lower prices for penicillin APIs – ...